血清和血浆中血管生成因子及抗血管生成因子的测定结果不同：临床实践中需要标准化。

Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice.

作者信息

Oggè Giovanna, Romero Roberto, Kusanovic Juan Pedro, Chaiworapongsa Tinnakorn, Dong Zhong, Mittal Pooja, Vaisbuch Edi, Mazaki-Tovi Shali, Gonzalez Juan M, Yeo Lami, Hassan Sonia S

机构信息

Perinatology Research Branch, NICHD/NIH/DHHS, Detroit, Michigan, USA.

出版信息

J Matern Fetal Neonatal Med. 2010 Aug;23(8):820-7. doi: 10.3109/14767050903366119.

DOI:10.3109/14767050903366119

PMID:20158394

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3426311/

Abstract

OBJECTIVE

The importance of an anti-angiogenic state as a mechanism of disease in preeclampsia is now recognized. Assays for the determination of concentrations of soluble vascular endothelial growth factor receptor (sVEGFR)-1, sVEGFR-2, placental growth factor (PlGF) and soluble endoglin (sEng) have been developed for research and clinical laboratories. A key question is whether these factors should be measured in plasma or serum. The purpose of this study was to determine if there are differences in the concentrations of these analytes between plasma and serum in normal pregnancy and in preeclampsia.

METHODS

Samples of maternal blood were obtained by venipuncture and collected in EDTA (lavender top) and serum collection tubes (red top). A standard laboratory procedure was implemented for the centrifugation, aliquoting and storage of samples. Plasma and serum from 70 women with normal pregnancies and 34 patients with preeclampsia were assayed for sVEGFR-1, sVEGFR-2, PlGF and sEng by ELISA. Nonparametric paired tests were used for analyses.

RESULTS

A significant difference between plasma and serum concentration was observed for sVEGFR-1 and sVEGFR-2 in normal pregnancy, and for sVEGFR-1, sVEGFR-2, PlGF and sEng in women with preeclampsia.

CONCLUSION

The concentrations of sVEGFR-1, sVEGFR-2, PlGF and sEng when measured in maternal plasma and in serum are different. Therefore, the matrix used for the assay (serum versus plasma) needs to be considered when selecting thresholds for predictive studies and interpreting the growing body of literature on this subject.

摘要

目的

抗血管生成状态作为子痫前期疾病机制的重要性现已得到认可。用于测定可溶性血管内皮生长因子受体（sVEGFR）-1、sVEGFR-2、胎盘生长因子（PlGF）和可溶性内皮糖蛋白（sEng）浓度的检测方法已被开发出来，供研究和临床实验室使用。一个关键问题是这些因子应该在血浆还是血清中进行检测。本研究的目的是确定在正常妊娠和子痫前期中，血浆和血清中这些分析物的浓度是否存在差异。

方法

通过静脉穿刺采集孕妇血液样本，分别收集于乙二胺四乙酸（EDTA，紫色帽）管和血清采集管（红色帽）中。对样本进行离心、分装和储存的标准实验室操作。采用酶联免疫吸附测定法（ELISA）对70例正常妊娠妇女和34例子痫前期患者的血浆和血清中的sVEGFR-1、sVEGFR-2、PlGF和sEng进行检测。采用非参数配对检验进行分析。